Microbiome Therapeutics Market Poised to Surge from $288.8M to $4B by 2034, Driven by Defined Consortia and Immuno-Oncology Innovations
核心洞察
The global microbiome therapeutics market reached USD 288.8 million in 2025 and is projected to hit USD 4,023.1 million by 2034, growing at a CAGR of 34.90%.
Seres Therapeutics achieved the first positive pivotal clinical results for a targeted microbiome drug candidate, SER-109, which received FDA Breakthrough Therapy and Orphan Drug Designations for recurrent C. difficile infection (搜索).
Enterome raised USD 19 million in Series E funding in June 2025 to advance OncoMimic-based cancer immunotherapies and inflammatory bowel disease (搜索) therapies into phase I trials.
The microbiome therapeutics industry is entering a transformative era, with the global market valued at USD 288.8 million in 2025 and projected to reach USD 4,023.1 million by 2034, reflecting a compound annual growth rate (CAGR) of 34.90%, according to Fortune Business Insights. This rapid expansion is fueled by rising research initiatives, increasing incidence of gut infections, and enhanced microbiome sequencing capabilities that are enabling a new generation of precision therapies targeting conditions ranging from recurrent C. difficile infection (搜索) to cancer.
The field encompasses diverse therapeutic modalities including probiotics, fecal microbiota transplantation (FMT), prebiotics, and engineered microbes, all aimed at restoring and maintaining the healthy balance of microbiota in the gut. As researchers, investors, and business leaders closely monitor developments, a cohort of nine companies has emerged as key drivers of biotech partnerships and clinical innovation.
Seres Therapeutics Leads with First Pivotal Microbiome Drug Success
Seres Therapeutics, a U.S.-based clinical-stage biotechnology company, has achieved a landmark milestone with its SER-109 program, which delivered the first positive pivotal clinical results from a targeted microbiome drug candidate. SER-109, an investigational microbiome therapeutic for recurrent C. difficile infections (CDI), received Orphan Drug Designation from the FDA and was subsequently designated as a breakthrough therapy. The FDA also accepted the company's Biologics License Application for the candidate.
The company's platform focuses on manufacturing therapies comprised of live selected bacterial consortia capable of establishing functional relationships with host cells and tissues to treat a wide range of diseases by modulating the human microbiome.
Enterome Advances OncoMimic Platform with Fresh Funding
In June 2025, French microbiome biotech Enterome raised USD 19 million in Series E funding to progress its cancer and inflammatory bowel disease (搜索) therapies into phase I trials. Enterome is developing cancer immunotherapies based on proteins produced by the human gut microbiome, termed "OncoMimic" proteins, which mimic those shed by cancer cells and can trigger the immune system to target specific tumors. The company's immunomodulatory drug platform represents a novel intersection of microbiome science and immuno-oncology.
Defined Consortia and Designer Bacteria Shape the Future
The industry is undergoing a fundamental shift away from traditional fecal microbiota transplants toward more precisely engineered solutions. Vedanta Biosciences (搜索), a U.S.-based clinical-stage biopharmaceutical company, is developing oral microbiome therapeutics based on defined bacterial consortia manufactured from pure, clonal bacterial cell banks, distinguishing its approach from donor stool-dependent FMT methods.
Synlogic, headquartered in Cambridge, Massachusetts, is advancing synthetic biotic drugs—live therapies designed to consume or alter disease-causing metabolites in the gastrointestinal tract without systemic absorption. These medications are engineered to provide local and acute healing benefits by treating the underlying problem directly in the gut.
Looking ahead, the field is moving toward "designer bacteria" that function as miniature factories inside the body, releasing precise amounts of medication only when needed. As Fortune Business Insights notes, researchers are increasingly utilizing artificial intelligence to identify and map the trillions of bacterial organisms in the GI tract, enabling the identification of specific medications required for diseases such as cancer, diabetes, and mental illnesses. The ultimate goal over the next decade will be ensuring these living drugs are safe, consistent, and capable of surviving in each patient's unique internal environment.
Strategic Collaborations Accelerate Development
Ferring Pharmaceuticals (搜索), headquartered in Switzerland, announced a research and development collaboration with Zürich-based PharmaBiome in December 2023 to advance next-generation microbiome-based biotherapeutics in gastroenterology. The deal grants Ferring exclusive rights to develop, manufacture, and commercialize these therapies within the gastroenterology field.
Meanwhile, MaaT Pharma, a French biotech developing microbiome ecosystem therapies to improve cancer patient outcomes, joined the Microbiome Therapeutics Innovation Group (MTIG) in July 2023, aligning with other companies focused on developing and researching FDA-approved drug candidates derived from the microbiome.
Nestlé Health Science and Enterome previously partnered to form Microbiome Diagnostics Partners (MDP), a joint venture aimed at creating and commercializing novel microbiome-based diagnostics, extending an initial monetary commitment made by Nestlé Health Science in April 2016.
Evelo Biosciences entered into an exclusive worldwide license agreement with the University of Chicago in April 2016 to develop and commercialize a microbiome-based cancer immunotherapy. The therapy, developed in the laboratories of Thomas Gajewski, professor of medicine and pathology at UChicago, employs select gut microbes to boost the immune system's attack on cancer cells and improve the efficacy of anti-cancer drugs.
Finch Therapeutics Group, which in January 2023 announced a focus on maximizing its intellectual property portfolio, has preclinical microbiome products in development targeting ulcerative colitis (搜索), Crohn's disease (搜索), and autism spectrum disorder.